Amendment No. 2 to the Research Collaboration Agreement, dated March 8, 2023, by and between Nkarta, Inc. and CRISPR Therapeutics AG

Exhibit 10.1

CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) OF THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK "[***]".

EXECUTION VERSION

Amendment No. 2

to the

RESEARCH Collaboration Agreement

This Amendment No. 2 to the Research Collaboration Agreement (the “Amendment”) is entered into as of March 8, 2023 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.

RECITALS

WHEREAS, the Parties desire to amend the Agreement to allow Nkarta Products to target [***] and provide for the calculation of milestone payments and royalties with respect thereto;

NOW, THEREFORE, in consideration of the respective covenants and agreements set forth herein, the Parties hereto agree as follows:

Amendments

“Nkarta Product” means [***].

“(e) notwithstanding anything to the contrary hereunder, Nkarta Products shall not [***].”

“10.1.1. Event Milestones. Nkarta shall, in connection with the first occurrence of each milestone event listed below with respect to each Nkarta Product that is not a [***] and each [***], as the case may be (whether achieved by Nkarta, its Affiliate or a sublicensee), pay CRISPR the milestone payments listed below in accordance with the procedure set forth in Section 10.1.2. Each such payment shall be non-refundable and non-creditable.

The term “Indication” as used above means, with respect to a particular Nkarta Product [***].

Solely for purposes of determining the milestone payment amount after a milestone event hereunder or calculating the royalty rate of Net Sales in Section 10.2.1(b), the term [***].”

“(b) During the Royalty Term, on an Nkarta Product-by-Nkarta Product basis, Nkarta shall pay to CRISPR a royalty on total annual Net Sales in the Territory equal to the following portions of Net Sales multiplied by the applicable royalty rate for such portion:

By way of example, if the annual Net Sales of a given Nkarta Product that is not a [***] in a particular Calendar Year are [***].”

MISCELLANEOUS

[SIGNATURE PAGE FOLLOWS]

* - * - * - *

2

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their representatives thereunto duly authorized as of the Amendment Effective Date.

[Signature Page to Amendment No. 2]